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Introduction
The mechanism of action of Onabotulinumtoxin type A
(onabotA) in chronic migraine (CM) is unknown.
Aim
To analyse a potential relationship between CGRP and
VIP levels and onabotA response.
Methods
CGRP and VIP levels were determined in antecubital vein
samples by ELISA outside a migraine attack prior to
treatment with onabotA. OnabotA was administered
according to PREEMPT at least twice. A patient was con-
sidered as a moderate responder when both: 1) moder-
ate-severe headaches were reduced by between 33-66%;
and 2) benefit in a visual scale of 0-100 was recorded
between 33-66%. Patients were considered as excellent
responders when both items improved > 66%. Those
without improvement of at least one-third in the two
items were considered as nonresponders.
Results
We assessed samples from 81 CM patients and 33 con-
trols. CGRP and VIP levels were significantly increased in
CM population. CGRP and, to a lesser degree, VIP levels
were significantly increased in responders vs nonrespon-
ders. For CGRP, a threshold of 72 pg/ml positively corre-
lated with 95% of nonresponders. The probability of
being a responder to onabotA was 28 times higher with a
CGRP level above the threshold of 72 pg/ml. Even
though the sensitivity for the calculated threshold for
VIP was poor, the probability that CM patients with low
CGRP levels will respond to onabotA was significantly
higher in those patients with high VIP levels.
Conclusions
Interictal CGRP and, to a lesser degree, VIP levels are of
help on predicting onabotA response. Supported by
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